Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
Paige Baldwin,1,* Anders W Ohman,2,* Shifalika Tangutoori,3 Daniela M Dinulescu,2,# Srinivas Sridhar1,3,4,#1Department of Bioengineering, Northeastern University, Boston, MA, USA; 2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 3Department o...
Guardado en:
Autores principales: | Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0d5df12d696417d8ac41da069330628 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin P, et al.
Publicado: (2018) -
Fatigue, mood, and sleep, during intraperitoneal chemotherapy: a pilot case control study
por: Heather Jim, et al.
Publicado: (2013) -
Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
por: Andreas Hallqvist, et al.
Publicado: (2021) -
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Francesca Bizzaro, et al.
Publicado: (2021) -
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu M, et al.
Publicado: (2018)